Lisata Therapeutics, Inc.

NasdaqCM:LSTA Stock Report

Market Cap: US$23.7m

Lisata Therapeutics Management

Management criteria checks 3/4

Lisata Therapeutics' CEO is Dave Mazzo, appointed in Jan 2015, has a tenure of 9.83 years. total yearly compensation is $1.41M, comprised of 48% salary and 52% bonuses, including company stock and options. directly owns 1.26% of the company’s shares, worth $297.61K. The average tenure of the management team and the board of directors is 4.1 years and 9 years respectively.

Key information

Dave Mazzo

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage48.0%
CEO tenure9.8yrs
CEO ownership1.3%
Management average tenure4.1yrs
Board average tenure9yrs

Recent management updates

Recent updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Mar 22
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Aug 04

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Caladrius suspends CLBS119 COVID-19 study

Dec 14

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

CEO Compensation Analysis

How has Dave Mazzo's remuneration changed compared to Lisata Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$1mUS$676k

-US$21m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$650k

-US$54m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$24m

Dec 31 2021US$1mUS$631k

-US$27m

Sep 30 2021n/an/a

-US$26m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$1mUS$613k

-US$8m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$19m

Dec 31 2019US$2mUS$597k

-US$19m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$2mUS$594k

-US$16m

Sep 30 2018n/an/a

-US$17m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$14m

Dec 31 2017US$1mUS$577k

-US$16m

Compensation vs Market: Dave's total compensation ($USD1.41M) is above average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.

CEO

Dave Mazzo (67 yo)

9.8yrs

Tenure

US$1,408,382

Compensation

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph D., served as Independent Non Executive Chairman at Visioneering Technologies, Inc. since February 28, 2020 until February 29,...

Leadership Team

NamePositionTenureCompensationOwnership
David Mazzo
President9.8yrsUS$1.41m1.26%
$ 297.6k
Kristen Buck
Executive VP of R&D and Chief Medical Officer3.2yrsUS$969.82k0.75%
$ 178.2k
James Nisco
Senior VP of Finance3.7yrsno data0.042%
$ 9.9k
Tariq Imam
Vice President of Business Development & Operations and Corporate Counsel1.8yrsno datano data
Gregory Berkin
Chief Information & Data Protection Officer4.1yrsno datano data
John Menditto
Vice President of Investor Relations & Corporate Communications6.9yrsno datano data
Gail Holler
Vice President of Human Resources5.8yrsno datano data
William Sietsema
Vice President of Global Regulatory Affairsno dataUS$400.18kno data

4.1yrs

Average Tenure

65yo

Average Age

Experienced Management: LSTA's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Mazzo
President9.8yrsUS$1.41m1.26%
$ 297.6k
Steven Klosk
Independent Director10.3yrsUS$120.00k0.0052%
$ 1.2k
Gregory Brown
Independent Chairman of the Board8.1yrsUS$149.50k0.0033%
$ 785.5
Heidi Henson
Independent Director2.2yrsUS$124.00k0%
$ 0
Gerald Nepom
Member of Type 1 Diabetes Scientific Advisory Boardno datano datano data
Robert Negrin
Immune Modulation Program Advisorno datano datano data
Robert Korngold
Immune Modulation Program Advisorno datano datano data
David Pearce
Member of Type 1 Diabetes Scientific Advisory Boardno datano datano data
David Horwitz
Immune Modulation Program Advisorno datano datano data
David Peritt
Immune Modulation Program Advisorno datano datano data
Noel Warner
Immune Modulation Program Advisorno datano datano data
Kevan Herold
Member of Type 1 Diabetes Scientific Advisory Boardno datano datano data

9.0yrs

Average Tenure

67yo

Average Age

Experienced Board: LSTA's board of directors are considered experienced (9 years average tenure).